TVGN

+ Watchlist + Portfolio

Tevogen Bio Holdings Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $6.72
52-Week Range: $3.64 – $39.00
Market Cap: $45.45M
P/E (TTM): —
EPS (TTM): -6.74
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -297.37%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.33
Debt/Equity: —
Total Debt: $9.44M
Free Cash Flow: $-3.05M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $62.61M

TVGN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$5.77M	$4.40M	$31.03M	$11.11M
Selling, General & Admin	$953.08K	$4.44M	$22.53M	$15.03M
Operating Expenses	$953.08K	$8.84M	$53.56M	$26.14M
Operating Income	-$953.08K	-$8.84M	-$53.56M	-$26.14M
EBITDA	$4.41M	-$58.89M	-$13.14M	-$25.57M
Pretax Income	$4.41M	-$60.48M	-$13.73M	-$26.28M
Net Income	$4.41M	-$60.48M	-$13.73M	-$26.28M
Diluted EPS	1.84	-19.12	-3.50	-8.08
Diluted Shares	2.40M	3.31M	2.93M	3.32M

TVGN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$129.19K	$1.05M	$1.28M	$552.37K
Receivables	$0.00	$0.00	$158.82K	$158.82K
Current Assets	$274.36K	$1.72M	$2.36M	$1.54M
Total Assets	$357.14M	$5.51M	$3.46M	$4.38M
Current Liabilities	$350.45K	$85.48M	$9.04M	$7.07M
Long-Term Debt	$39.30M	$14.22M	$1.00M	$4.40M
Total Debt	$40.01M	$95.42M	$2.89M	$7.50M
Total Liabilities	$15.06M	$99.93M	$10.14M	$12.62M
Retained Earnings	-$14.78M	-$99.66M	-$113.39M	-$139.66M
Shareholders' Equity	$342.08M	-$94.43M	-$6.67M	-$8.23M
Working Capital	-$76.10K	-$83.76M	-$6.68M	-$5.53M
Net Debt	$33.81M	$93.88M	$1.37M	$5.50M

TVGN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$215.40K	-$8.17M	-$12.00M	-$12.33M
Capital Expenditure	-$479.04K	-$133.00K	—	-$64.44K
Free Cash Flow	-$215.40K	-$8.30M	-$12.00M	-$12.39M
Depreciation & Amortisation	$230.82K	$378.36K	$403.58K	$509.20K
Stock-Based Compensation	$4.58M	$0.00	$40.76M	$16.22M
Investing Cash Flow	$0.00	-$133.00K	$0.00	-$64.44K
Financing Cash Flow	$0.00	$3.87M	$12.23M	$11.66M
Share Repurchases	$0.00	-$342.98M	—	—
Net Change in Cash	-$215.40K	-$4.43M	$230.60K	-$730.62K

TVGN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.20M	$2.70M	$3.11M	$2.11M	$3.13M	$3.28M
Selling, General & Admin	$7.16M	$2.74M	$2.62M	$2.50M	$2.27M	$2.38M
Operating Expenses	$10.36M	$5.44M	$5.73M	$4.61M	$5.40M	$5.66M
Operating Income	-$10.36M	-$5.44M	-$5.73M	-$4.61M	-$5.40M	-$5.66M
EBITDA	-$10.24M	-$5.15M	-$5.64M	-$4.52M	-$5.32M	-$5.60M
Pretax Income	-$10.37M	-$5.50M	-$5.73M	-$4.68M	-$5.45M	-$5.76M
Net Income	-$10.37M	-$5.50M	-$5.73M	-$4.68M	-$5.45M	-$5.76M
Diluted EPS	-3.25	-1.71	-1.50	—	-1.61	-1.52
Diluted Shares	3.23M	3.29M	3.92M	—	3.49M	3.83M

TVGN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$1.97M	$685.23K	$1.04M	$552.37K	$692.30K	$1.08M
Receivables	$158.82K	$158.82K	$158.82K	$158.82K	$158.82K	$158.82K
Current Assets	$3.08M	$2.06M	$2.12M	$1.54M	$2.14M	$2.01M
Total Assets	$4.07M	$4.27M	$4.49M	$4.38M	$4.92M	$4.73M
Current Liabilities	$8.72M	$8.08M	$6.74M	$7.07M	$7.27M	$6.15M
Long-Term Debt	$3.00M	$4.40M	$4.40M	$4.40M	$6.40M	$6.40M
Total Debt	$4.82M	$7.56M	$7.53M	$7.50M	$9.47M	$9.44M
Total Liabilities	$11.79M	$13.75M	$12.32M	$12.62M	$14.76M	$13.62M
Retained Earnings	-$123.75M	-$129.26M	-$134.98M	-$139.66M	-$145.11M	-$150.87M
Shareholders' Equity	-$7.72M	-$9.48M	-$7.82M	-$8.23M	-$9.84M	-$8.89M
Working Capital	-$5.64M	-$6.02M	-$4.62M	-$5.53M	-$5.13M	-$4.14M
Net Debt	$2.68M	$5.37M	$5.01M	$5.50M	$7.36M	$6.97M

TVGN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$3.31M	-$3.19M	-$3.65M	-$2.18M	-$2.73M	-$3.01M
Free Cash Flow	-$3.31M	-$3.19M	-$3.65M	-$2.25M	-$2.73M	-$3.01M
Depreciation & Amortisation	$105.40K	$290.78K	$27.23K	$85.79K	$59.05K	$60.14K
Stock-Based Compensation	$7.29M	$3.24M	$3.24M	$2.45M	$2.85M	$3.29M
Investing Cash Flow	$0.00	$0.00	$0.00	-$64.44K	$0.00	$0.00
Financing Cash Flow	$4.00M	$1.90M	$4.00M	$1.76M	$2.87M	$3.40M
Net Change in Cash	$691.94K	-$1.29M	$351.87K	-$484.72K	$139.93K	$389.85K

Market Snapshot

About

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company developing off-the-shelf, genetically unmodified T cell therapeutics. The company focuses on treating infectious diseases, cancers, and neurological disorders using its proprietary ExacTcell technology platform. Tevogen aims to make personalized cellular immunotherapy more accessible and affordable.